Trials / Completed
CompletedNCT02919475
Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis
A Multicenter, Randomized, Double-blind, PlacebO-controlled, Parallel-group Study to EValuate the Efficacy and Safety of JTE-051 Administered for 12 Weeks to Subjects With Active Rheumatoid Arthritis (MOVE-RA)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Akros Pharma Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy, safety, tolerability and pharmacokinetics (PK) of JTE-051 administered for 12 weeks in subjects with active rheumatoid arthritis who are receiving background non-biologic disease-modifying anti-rheumatic drug therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JTE-051 | Active drug tablets containing JTE-051 |
| DRUG | Placebo | Placebo tablets identical in appearance to the active drug tablets |
Timeline
- Start date
- 2016-09-14
- Primary completion
- 2018-06-25
- Completion
- 2018-06-25
- First posted
- 2016-09-29
- Last updated
- 2021-06-14
- Results posted
- 2021-06-14
Locations
39 sites across 10 countries: United States, Argentina, Bulgaria, Colombia, Mexico, Peru, Poland, Romania, Russia, Ukraine
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02919475. Inclusion in this directory is not an endorsement.